Aliskiren + Hydrochlorothiazide + Amlodipine
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Essential Hypertension ( Mild to Moderate)
Conditions
Essential Hypertension ( Mild to Moderate)
Trial Timeline
Sep 1, 2008 → Aug 1, 2009
NCT ID
NCT00765947About Aliskiren + Hydrochlorothiazide + Amlodipine
Aliskiren + Hydrochlorothiazide + Amlodipine is a approved stage product being developed by Novartis for Essential Hypertension ( Mild to Moderate). The current trial status is completed. This product is registered under clinical trial identifier NCT00765947. Target conditions include Essential Hypertension ( Mild to Moderate).
What happened to similar drugs?
14 of 20 similar drugs in Essential Hypertension ( Mild to Moderate) were approved
Approved (14) Terminated (2) Active (6)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00765947 | Approved | Completed |
Competing Products
20 competing products in Essential Hypertension ( Mild to Moderate)